Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Plasma Cell Leukemia
NCT03591744Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Sep 2018
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in plasma cell leukemia (PCL), sponsored by City of Hope. Primary endpoint: Incidence of adverse events at 30 days. Planned start Sep 2018; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT03591744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591744.